Lee Jinkwon, Lee Jeongmin, Tae In Hwan, Kang Yunsang, Kim Jinsan, Kim Sarang, Yang Haneol, Park Kunhyang, Park Doo-Sang, Kim Dae-Soo, Cho Hyun-Soo
Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
Korea University of Science and Technology, Daejeon 34113, Republic of Korea.
J Microbiol Biotechnol. 2025 Jul 18;35:e2505001. doi: 10.4014/jmb.2505.05001.
Colorectal cancer (CRC) has a very high mortality rate worldwide. Although various therapies have been developed to treat CRC, the need for novel therapeutic approaches has been increasing due to severe side effects and limited efficacy of current treatments. Recently, although research on the gut microbiome and its association with colon cancer has been growing, the mechanisms of gut microbiome inhibition in CRC remain insufficiently understood. Thus, in this study, we investigated the growth-inhibitory effects of the culture supernatant of DS3316, isolated from infant feces, on CRC cell lines (HCT116 and SNUC5). And RNA-seq analysis revealed an increase in apoptosis-related terms induced by DS3316 treatment. Also, we found the non-toxicity of DS3316 in human iPSC-derived intenstine organoid. Thus, we suggested that DS3316 inhibits the growth of colorectal cancer cell lines without affecting normal cells. And DS3316 is expected to be a promising candidate for the development of microbiome-based colorectal cancer therapies. Furthermore, its combined use with various colorectal cancer treatment methods could lead to the proposal of more effective therapeutic approaches.
结直肠癌（CRC）在全球范围内具有非常高的死亡率。尽管已经开发出各种疗法来治疗CRC，但由于当前治疗的严重副作用和有限疗效，对新型治疗方法的需求一直在增加。最近，尽管关于肠道微生物群及其与结肠癌的关联的研究不断增加，但CRC中肠道微生物群抑制的机制仍未得到充分了解。因此，在本研究中，我们研究了从婴儿粪便中分离出的DS3316的培养上清液对CRC细胞系（HCT116和SNUC5）的生长抑制作用。RNA测序分析显示，DS3316处理诱导的凋亡相关术语增加。此外，我们发现DS3316对人诱导多能干细胞来源的肠道类器官无毒。因此，我们认为DS3316在不影响正常细胞的情况下抑制结直肠癌细胞系的生长。并且DS3316有望成为基于微生物群的结直肠癌治疗开发的有前途的候选物。此外，将其与各种结直肠癌治疗方法联合使用可能会提出更有效的治疗方法。
